Should I buy Zomedica stock in 2025?

What is Zomedica?

How much is the Zomedica stock?

The price of Zomedica stock is falling this week. As of today, Zomedica shares are trading at USD $0.0451, marking a 24-hour decline of 4.25% and a 3.64% drop over the past week. The company has a market capitalisation of $44.38 million, with an average three-month trading volume of 5.64 million shares. Currently, the company has no P/E ratio as it is not yet profitable, no dividend yield, and a beta of 1.63, indicating higher-than-average volatility. This elevated volatility means investors should be mindful of potential price swings when evaluating Zomedica for their NZ portfolio.

Our complete analysis on the Zomedica stock

After a rigorous evaluation of Zomedica’s most recent financial disclosures and a comprehensive review of the stock’s three-year trajectory, our proprietary analytical framework—integrating key financial data, technical metrics, competitive dynamics, and real-time market signals—suggests a compelling inflection point is emerging. Zomedica’s evolution in the high-potential veterinary diagnostics sector, combined with notable strategic momentum, raises a critical question for 2025: why might Zomedica again prove to be a strategic entry point into the animal health technology sector for investors seeking asymmetric upside?

Recent Performance and Market Context

Over the past 12 months, Zomedica has experienced significant price volatility, with the stock trading at US$0.0451 as of 30 May 2025—down 73% year-on-year and 64.6% over the last six months. While such declines can at first glance be daunting, context is essential: the past quarters have seen a repricing across emerging growth stocks, especially those listed on the OTCQB Venture Market following Zomedica’s March 2025 transition from the NYSE American. Notably, recent trading has stabilised in the $0.0426–0.0480 range, consistent with tactical support zones established over multiple sessions.

Several positive events underpin resilience in Zomedica’s story:

• Robust operational continuity: The platform’s migration to OTCQB has not disrupted product development or partner engagement, as confirmed by uninterrupted revenue growth.
• Innovation momentum: In May 2025, Zomedica launched an improved equine insulin diagnostic on its TRUFORMA system, illustrating continual pipeline advancement.
• Executive reinforcement: The January 2025 appointment of CFO Scott A. Jordan brought deep sector experience to the management bench, enhancing financial and operational governance.

The global veterinary diagnostics market remains buoyant, projecting high-single-digit annual growth driven by pet ownership trends, increased spend on companion animal healthcare, and accelerating demand for rapid, point-of-care solutions—a dynamic especially relevant in mature, innovation-led economies such as New Zealand and Australia. This sector context provides fresh wind to Zomedica’s near-term outlook and may explain why institutional and strategic investors are watching sector undervaluations closely for entry opportunities.

Technical Analysis

Technical signals point to a scenario of potential bullish reversal:

• Relative Strength Index (RSI): Currently at 39.67, Zomedica’s RSI is in oversold territory, often interpreted as a precursor to price mean reversion and upward momentum in the short term.
• Support and Resistance: The $0.0151 level stands as major 52-week support, while $0.1769 represents an established resistance barrier. The proximity of the price to the lower band, paired with this robust support, often sets the stage for high-reward technical positioning.
• Momentum Structure: Regular trading above volume averages amid limited downwards extension suggests that capitulation may be behind us, with buyers gradually building positions on weakness.
• MACD & Moving Averages: While explicit MACD and moving averages data are not available as of the analysis date, the flattening of the downtrend and narrowing daily price range are classic hallmarks of a basing pattern and a technical bottoming process.

Taken together, these elements create an attractive backdrop for accumulation strategies—a view further supported by the consensus analyst price target of $0.25, nearly fivefold above current levels.

Fundamental Analysis

Zomedica’s fundamentals reinforce the technical base, providing a multi-layered reason to monitor closely for renewed investor interest:

• Consistent Revenue Growth: Q1 2025 revenue reached $6.5 million, up 3% year-over-year, while full-year 2024 sales grew 8.3% to $27.29 million. This sequential expansion—especially in a challenging capital market context—signals resilience.
• Healthy Gross Margins: At 68%, gross margins remain industry-leading, underpinning scalable business economics once sufficient top-line velocity is achieved.
• Investment in Growth: The net loss of $46.98 million is balanced by nearly $65 million in cash, offering financial flexibility and a runway for innovation and market expansion.
• Strategic Expansion: Zomedica is aggressively building out its international footprint, leveraging distributive agreements in Europe and other high-growth regions, positioning itself as a global, not just North American, player.
• Product Innovation: The TRUFORMA point-of-care platform continues to extend Zomedica’s market lead. The recent rollout of eight new diagnostics tests within an 18-month window exemplifies a robust R&D cycle that resonates strongly in tech-weighted investment strategies.
• Attractive Valuation: Though the company remains pre-profit and carries no P/E or PEG ratio, its low price-to-sales ratio (market cap/revenue) for a niche, high-potential medtech firm presents a value thesis for risk-tolerant, growth-focused portfolios.

These fundamentals support the notion that Zomedica’s current valuation discounts much of the near-term operational risk while offering multiple optionalities for upside.

Volume and Liquidity

One of the most revealing markers of institutional or market confidence is trading activity:

• Sustained Volume: With an average daily volume of 5.64 million shares over the past three months, Zomedica’s stock demonstrates an ample liquidity profile—especially notable for a small-cap stock on the OTCQB market.
• Favourable Float: The share structure, with roughly 980 million shares outstanding, allows for price agility without excessive dilution risk. High trading velocity can attract momentum traders, adding further support to valuation discovery on positive news.

For NZ-based investors accustomed to trading international equities, the liquidity profile suggests easy entry and exit—particularly critical for tactical investors seeking to time catalysts.

Catalysts and Positive Outlook

Zomedica’s near- and medium-term potential is driven by a robust pipeline and evolving market context:

• Major Product Initiatives: The rollout of next-generation equine diagnostics and expansion of the PulseVet therapeutic franchise (up 8% in Q1) signal ongoing product innovation.
• Strategic Partnerships: Deepening ties with Cresilon around Vetigel—an advanced hemostatic solution—could trigger both top-line growth and enhanced brand moat.
• Regulatory and Sector Tailwinds: The veterinary tech field is benefiting from regulatory reforms that expedite point-of-care device adoption in key markets. In New Zealand, ongoing upgrades to animal care systems and rising pet insurance coverage further underpin future demand.
• ESG Positioning: Animal health and welfare themes are at the forefront of ESG-conscious portfolios. Zomedica’s focus on minimally invasive, rapid diagnostics represents a strong case for inclusion in responsible investment frameworks.

With an analyst consensus price objective at $0.25 and the upcoming 2025-2026 product cycle, several positive inflection points may be on the near horizon.

Investment Strategies

Given the convergence of technical and fundamental positives, several strategies can be envisaged for positioning in Zomedica:

• Short-term entry: Tactical investors may look to accumulate shares near clear technical support ($0.0451 and lower), anticipating a rebound from oversold zones as sentiment turns.
• Medium-term exposure: Buyers can exploit the current base-building process, aiming to capitalise on catalysts expected from new product launches or strategic partnership news over the next 6–12 months.
• Long-term positioning: For those with a multi-year horizon, Zomedica’s drive toward breakeven at $50 million revenue, expanding international presence, and ongoing product innovation could serve as powerful themes for sustained capital appreciation—particularly as the stock trades at a marked discount to sector growth peers.

A disciplined dollar-cost-averaging approach may also suit those seeking to smooth volatility and compound into a potential recovery, in alignment with the risk-reward dynamic typical in the emerging health tech segment.

Is it the right time to buy Zomedica?

In summary, the convergence of favorable technical signals, sturdy revenue growth, ample liquidity, and a pipeline rich with near-term catalysts creates a compelling case for renewed interest in Zomedica. The stock’s multi-year retracement has reset expectations to a level where the asymmetry between risk and opportunity seems notably attractive—especially when set against its current valuation and global sector trends. With continued innovation, a clear path to international expansion, and strong fundamentals in an expanding animal health market, Zomedica appears well-positioned to anchor a fresh bullish phase. For those seeking exposure to high-upside, niche technology stories, this stock demands serious consideration as a strategic allocation within a growth-oriented portfolio.

In a landscape increasingly shaped by technological and health-related innovation, Zomedica’s current price zone may represent an excellent opportunity to participate in the resurgence of a truly differentiated player in the veterinary diagnostics space.

How to buy Zomedica stock in New Zealand?

Buying Zomedica (ZOMDF) stock online is straightforward and secure when you use a regulated broker, as these platforms are subject to strict oversight and investor protections. Investors in New Zealand have two practical options: purchasing Zomedica shares outright (spot buying) or trading them as Contracts for Difference (CFDs), allowing flexibility depending on your goals and risk tolerance. Each method has its specifics, which we detail below. For a comparison of regulated brokers active in NZ, see the table further down this page.

Cash buying

Spot (cash) buying means purchasing Zomedica shares directly via your online brokerage account, where you own the actual shares in your name. Typical fees for international stocks include a fixed commission per order—often around NZ$5 to NZ$15, depending on the broker.

Example

Suppose Zomedica is trading at US$0.0451, and you want to invest NZ$1,000 (approximately US$610 at a rate of 0.61). After a brokerage fee of NZ$5, you’ll have around NZ$995 to invest, equaling about US$606. This allows you to acquire roughly 13,438 shares (US$606 / US$0.0451).

✔ Gain scenario: If the share price climbs by 10% to US$0.0496, your 13,438 shares would be worth around US$666 (13,438 × US$0.0496 ≈ US$666), which equals approximately NZ$1,091 at the same exchange rate.
Result: That’s a NZ$91 gross gain—about +9.1% on your initial investment, before tax and currency effects.

Trading via CFD

CFD trading lets you speculate on Zomedica’s share price movement without owning the shares. CFDs (Contracts for Difference) are leveraged products, popular for their flexibility both upwards (rising prices) and downwards (falling prices). You pay the spread (the broker’s buy/sell difference) and possible overnight financing if you hold positions for more than a day.

Example

Imagine you deposit NZ$1,000 and use 5x leverage with your CFD broker. This means your market exposure is NZ$5,000 (or around US$3,050). If Zomedica’s share price rises by 8%, your position value increases by 8% × 5 = 40%.

✔ Gain scenario: A 40% gain on your NZ$1,000 stake equals NZ$400 in profit (excluding fees and currency impact).

Final advice

Before investing in Zomedica or any US-listed share, it’s vital to compare the fees, account minimums, and conditions among available brokers in New Zealand (see our detailed comparison table below). The best method depends on your profile and objectives: choose spot buying if you prefer to own the shares for the long term, or opt for CFDs if you seek trading flexibility with leverage and both rising and falling markets. Always assess risks and costs carefully before you begin.

Our 7 tips for buying Zomedica stock

The latest news about Zomedica

Zomedica reported a 3% year-over-year revenue increase in Q1 2025, supported by a robust 68% gross margin. This positive financial signal reflects sustained demand for veterinary diagnostics products, a key factor for growth sustainability. For New Zealand stakeholders, where the pet healthcare market is expanding and demand is rising for innovative point-of-care solutions, Zomedica’s financial progress may indicate potential for international product adoption or future partnerships with regional distributors.

The company launched an enhanced equine insulin test for its TRUFORMA platform in May 2025, underscoring its R&D commitment. This innovation targets the equine veterinary segment, which has strategic relevance in New Zealand given the country’s significant equine and livestock industries. The new test positions Zomedica favorably to serve specialized veterinary needs, aligning with clinical trends in major NZ animal health practices and supporting the firm’s differentiator as a leader in non-invasive, rapid veterinary diagnostics.

Zomedica’s liquidity remains strong at $65 million, reinforcing operational resilience and funding for growth initiatives. With substantial cash reserves on hand, the company is well-placed to weather industry challenges, develop new products, and potentially expand its global footprint. This financial stability may be reassuring for New Zealand investors and partners who prioritize sustainable operations and ongoing innovation in their collaborating companies.

The company continues its international expansion via European partnerships, potentially paving the way for broader distribution opportunities. While no direct New Zealand partnership has been announced in the last week, this strategic approach demonstrates Zomedica’s openness to global market penetration. For NZ-based veterinary suppliers and clinics watching international health trends, such activities may foreshadow future availability of advanced diagnostic platforms like TRUFORMA in the region.

Zomedica remains a niche market leader in point-of-care veterinary diagnostics, complemented by a confirmed growth trajectory in its PulseVet therapeutic segment (+8% in Q1 2025). This dual focus on diagnostics and therapeutics aligns with the sophisticated needs of New Zealand’s veterinary sector, which is increasingly adopting advanced in-clinic technologies. These developments bolster Zomedica’s long-term value proposition and reinforce its relevance for professionals tracking innovation and product availability within NZ’s animal health ecosystem.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.